No one will ever truly grasp the horrifying, never-ending ordeal,” Jada Jones told The Post. And it can happen to anyone.

Medically reviewed by William Truswell, MD Eczema is a long-term condition where an overactive immune response causes skin inflammation (swelling) and irritation. Eczema leads to dry, itchy patches of ...

HUNTINGTON BEACH, Calif. — If the number of recent drug approvals for atopic dermatitis (AD) is overwhelming, the future is unlikely to be any less challenging: According to the National Eczema ...

LOS ANGELES, CA, USA I July 14, 2025 I Turn Therapeutics today announced the initiation of a randomized, double-blind, vehicle-controlled clinical trial ...

Considering dual biologic therapy for psoriasis or eczema? Get a firsthand account of navigating insurance, potential side effects, and treatment outcomes.

Nektar Therapeutics shares doubled in early trading Tuesday after the U.S. biotech firm said it reached its targets in a ...

The first new type of drug in decades to treat the troubling skin disease eczema moved a step closer to market last week as the government's scientific advisors unanimously declared Protopic ...

Apogee Therapeutics said its antibody treatment alleviated signs and symptoms of atopic dermatitis far more than a placebo — ...

The Food and Drug Administration had recently approved a new drug for the treatment of atopic dermatitis (eczema), which can significantly improve symptoms.

Eli Lilly and Company LLY announced that the FDA has granted approval to its IL-13 inhibitor Ebglyss (lebrikizumab) for treating moderate-to-severe atopic dermatitis, also called eczema. Ebglyss ...

INDIANAPOLIS (WISH) — The U.S. Food and Drug Administration has approved Lilly’s new treatment for moderate to severe eczema. The Indianapolis-based company says the newly approved injection ...

Nektar Therapeutics’ biologic drug rezpegaldesleukin takes a new approach to atopic dermatitis, or eczema, stimulating proliferation of immune cells that tamp down excessive immune responses ...